First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms
October 17, 2019 05:00 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and SAN MATEO, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by...
Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
October 17, 2019 05:00 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif., and BASEL, Switzerland, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and...
Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
October 10, 2019 08:30 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif., and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and...
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
September 06, 2019 03:01 ET
|
Myovant Sciences, Inc.
Roivant’s ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly...
CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27, 2019 13:26 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated today at 8:30 AM ET. The date for Lynn Seely's presentation was...
Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27, 2019 08:30 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative...
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
August 20, 2019 08:30 ET
|
Myovant Sciences, Inc.
- Top-line data for SPIRIT 2 expected in first quarter of 2020 - Company on track to announce top-line results from SPIRIT 1 in second quarter of 2020 BRISBANE, Calif., and BASEL, Switzerland, Aug. ...
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
August 06, 2019 16:05 ET
|
Myovant Sciences, Inc.
-Positive results from both Phase 3 LIBERTY trials and bioequivalence study supports submission of NDA for uterine fibroids which is expected by year end 2019 and MAA which is expected by Q1-2020- ...
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
July 23, 2019 07:30 ET
|
Myovant Sciences, Inc.
Primary efficacy endpoint met with 71.2% response rate (p < 0.0001); women experienced, on average, an 84.3% reduction in menstrual blood loss (p < 0.0001)Achieved six key secondary endpoints...
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
July 22, 2019 16:01 ET
|
Myovant Sciences, Inc.
BRISBANE, Calif. and BASEL, Switzerland, July 22, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative...